Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
An Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Three Dosing Regimens of Oral AT2220 in Patients With Pompe Disease
Sponsor: Amicus Therapeutics
Terminated
Per protocol, 3 sequential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.
A PHASE2 clinical study on Pompe Disease, this trial is terminated or withdrawn. The trial is conducted by Amicus Therapeutics and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amicus Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .